S 23521 decreases food intake and body weight gain in diet-induced obese rats.

@article{Claret2004S2D,
  title={S 23521 decreases food intake and body weight gain in diet-induced obese rats.},
  author={Marc Claret and Helena Corominola and Ignasi Canals and Bel{\'e}n Nadal and Alain Chavanieu and Bruno Pfeiffer and Pierre Renard and Carmen Gorostiaga and Philippe Delagrange and G{\'e}rard Grassy and Ramon Gomis},
  journal={Obesity research},
  year={2004},
  volume={12 10},
  pages={
          1596-603
        }
}
OBJECTIVE To investigate the effect of S 23521, a new glucagon-like peptide-1-(7-36) amide analogue, on food intake and body weight gain in obese rats, as well as on gene expression of several proteins involved in energy homeostasis. RESEARCH METHODS AND PROCEDURES Lean and diet-induced obese rats were treated with either S 23521 or vehicle. S 23521 was given either intraperitoneally (10 or 100 microg/kg) or subcutaneously (100 microg/kg) for 14 and 20 days, respectively. Because the low-dose… Expand
Rice bran water extract attenuates pancreatic abnormalities in high-fat diet-induced obese rats
Purpose: To investigate the protective potential of rice bran water extract (RBE) from Khao Dawk Mali 105 on pancreatic abnormalities in high-fat diet (HFD)-induced obese rats. Methods: MaleExpand
Benjakul supplementation improves hepatic fat metabolism in high-fat diet-induced obese rats
Purpose: To evaluate the effects of Benjakul water extract (BWE) supplementation for the prevention of hepatic fat metabolic dysfunction in a rat obesity model induced by a high-fat diet (HFD).Expand
Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride.
TLDR
The results show that this HFD/fructose/STZ diet could be used to induce an effect that mimics human type 2 diabetes with its metabolic disturbances and is suitable for screening the antidiabetic agents used for management of this disease. Expand
Vasoprotective effects of rice bran water extract on rats fed with high-fat diet
TLDR
Rice bran water extract exhibited vasoprotective effects in the high-fat diet-induced obesity condition by modulating the expression of eNOS, NF-κB, and CD36 and metabolic parameters. Expand
Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study.
TLDR
It is suggested that liraglutide may alter the circulating levels of hormones important in energy homeostasis that, in turn, influence CNS perception of food cues, which could possibly lead to compensatory changes in energyHomeostasis in diabetics. Expand
A Comparative Genotoxicity Study of a Supraphysiological Dose of Triiodothyronine (T3) in Obese Rats Subjected to Either Calorie-Restricted Diet or Hyperthyroidism
TLDR
It is indicated that regardless of diet, a supraphysiological dose of T3 causes genotoxicity and potentiates oxidative stress and the ORS group, compared to OR animals, showed higher genot toxicity. Expand
Influência do hormônio tireoidiano e da restrição alimentar sobre dano de DNA em animais obesos
TLDR
The diet adopted in this study, rich in AGl, caused obesity and induced DNA damage and the supraphysiological dose of T3, provided to OB group reduced body weight and adiposity, but highlighted the production of DNA damage. Expand
Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLD
TLDR
It is demonstrated in a rat model of the metabolic syndrome that shows features of NAFLD, that liver endothelial dysfunction occurs before the development of fibrosis or inflammation. Expand
Poly‐GLP‐1, a novel long‐lasting glucagon‐like peptide‐1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta‐cell proliferation
TLDR
A new polymer of glucagon‐like peptide‐1 was developed by prodrug strategy, termed Poly‐GLP‐1, and its pharmacological properties were investigated. Expand
Sodium tungstate decreases the phosphorylation of tau through GSK3 inactivation
Tungstate treatment increases the phosphorylation of glycogen synthase kinase‐3β (GSK3β) at serine 9, which triggers its inactivation both in cultured neural cells and in vivo. GSK3 phosphorylationExpand
...
1
2
...

References

SHOWING 1-10 OF 30 REFERENCES
Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats.
TLDR
Partial tolerance to the anorectic effect of exendin-4 in lean rats may have been due to elevated plasma corticosterone and depressed plasma leptin levels, but other counter-regulatory mechanisms seem to play a role in obese Zucker rats. Expand
Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats
TLDR
The hypothesis that GLP-1, acting in the CNS, is an important regulator of long-term food intake and body weight of lean Long Evans rats and fatty Zucker rats is not supported. Expand
Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.
TLDR
The combination of appetite reduction, decreased fat deposition and an improvement in the parameters associated with glucose intolerance makes a case for the use of exendin-4 as a treatment for diabetes. Expand
Differential Effects of Intracerebroventricular Glucagon-Like Peptide-1 on Feeding and Energy Expenditure Regulation
TLDR
The data suggest that central GLP-1 may be an important factor controlling negative energy balance in both the lean and obese Zucker rats. Expand
Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.
TLDR
Findings show that peripheral (s.c.) administration of both GLP-1 receptor agonists also induces satiety and weight loss in rats, and suggest the potential usefulness of exendin-4 as a therapeutic tool for the treatment of diabetes and/or obesity. Expand
Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives.
TLDR
The present review aims to describe the role of GLP-1 in the central regulation of feeding and to discuss its possible application in the pharmacotherapy of obesity. Expand
Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.
TLDR
The present series of experiments show that GLP-1 is fully capable of inhibiting food intake in rats via a peripherally accessible site and may prove efficient as weight-reducing therapeutic agents for overweight patients with type 2 diabetes. Expand
Repeated Intracerebroventricular Administration of Glucagon-Like Peptide-1-(7-36) Amide or Exendin-(9-39) Alters Body Weight in the Rat* *This work was supported by the United Kingdom Medical Research Council.
TLDR
It is reported that repeated intracerebroventricular injection of GLP-1 or the GLp-1 receptor antagonist, exendin-(9–39), affects food intake and body weight. Expand
Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus.
TLDR
It is concluded that truncated GLP-1, in addition to its well-known incretin effect, is capable of augmenting insulin action in peripheral tissues of diabetics, which can contribute, in part, to improve glucose intolerance in OLETF rats. Expand
Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats.
TLDR
The results indicate that central GLP-1 produces aversive side effects, and it is argued that these nonspecific effects may explain the anorectic actions of GLp-1. Expand
...
1
2
3
...